PACB - Pacific Biosciences of California, Inc.
| Previous close | 3.72 |
| Open | 3.73 |
| Bid | 3.63 x 2200 |
| Ask | 4.00 x 3100 |
| Day's range | 3.63 - 3.75 |
| 52-week range | 2.02 - 5.70 |
| Volume | 545,947 |
| Avg. volume | 815,993 |
| Market cap | 487.945M |
| Beta | 3.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.82 |
| Earnings date | 31 Jul 2018 - 6 Aug 2018 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.51 |
- Motley Fool•6 days ago
Here's Why Pacific Biosciences of California, Inc. Rose 40.3% in June
The DNA sequencing leader announced upgrades to some of its core offerings.
- Motley Fool•20 days ago
Why Pacific Biosciences of California Inc. Plunged Today
Reports of an escalation in trade tensions between the U.S. and China caused the gene-sequencing stock to fall.
- Simply Wall St.•21 days ago
Pacific Biosciences of California Inc’s (NASDAQ:PACB) Earnings Dropped -17.25%, How Did It Fare Against The Industry?
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Pacific Biosciences of California Inc’s (NASDAQ:PACB) track record on a highRead More...
- Motley Fool•23 days ago
Better Buy: Illumina, Inc. vs. Pacific Biosciences of California
Which stock wins in a match-up between these two gene-sequencing leaders?
- Zacks•last month
Pacific Biosciences to Gain From New Genome Sequencing Tools
Pacific Biosciences' (PACB) new multiplexing kit to make genome sequencing faster and cost-effective.
- Motley Fool•last month
Is This Why Pacific Biosciences of California Surged This Week?
Investors appear pleased with the Sequel System's latest update.
- Zacks•last month
Why Is Pacific Biosciences (PACB) Down 6.7% Since its Last Earnings Report?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool•2 months ago
Here's Why Pacific Biosciences of California Is Falling Today
Disappointing quarterly results weighed on the stock.
- Motley Fool•2 months ago
For Pacific Biosciences of California, a First Quarter Hurt by Shipment Delays
The gene-sequencing company received plenty of orders for its Sequel systems in the first quarter, but customers weren't ready for most of them.
- Zacks•2 months ago
Pacific Biosciences (PACB) Loss Wider Than Expected in Q1
Pacific Biosciences (PACB) Q1 earnings and revenues miss estimates; Sequel orders rise.
- Associated Press•2 months ago
Pacific Biosciences: 1Q Earnings Snapshot
The Menlo Park, California-based company said it had a loss of 20 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Zacks•3 months ago
Pacific Biosciences Gains as HudsonAlpha Picks Sequel System
Pacific Biosciences (PACB) sees increasing use of Sequel Sequencing System in pediatric and plant biologic case studies.
- Zacks•4 months ago
Pacific Biosciences Unveils New Version of Sequel Software
Pacific Biosciences (PACB) enhances performance and cost-effectiveness of the Sequel System.
- Zacks•4 months ago
Pacific Biosciences (PACB) Down 15.6% Since Earnings Report: Can It Rebound?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•5 months ago
Are Options Traders Betting on a Big Move in Pacific Biosciences (PACB) Stock?
Surging implied volatility makes Pacific Biosciences (PACB) stock lucrative to the option traders.
- Zacks•5 months ago
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
- Motley Fool•5 months ago
What's Behind Pacific Biosciences of California's Sinking Fourth-Quarter Sales
The gene-sequencing company didn't have much good news from the fourth quarter, but better days could be ahead.
- Associated Press•5 months ago
Pacific Biosciences reports 4Q loss
The Menlo Park, California-based company said it had a loss of 18 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Zacks•5 months ago
Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock
Pacific Biosciences (PACB) needs investors to pay close attention to the stock based on moves in the options market lately.
- Motley Fool•6 months ago
Here's Why Pacific Biosciences of California Is Surging Today
Another big purchase order for the genome sequencing equipment manufacturer ahead of its full-year 2017 earnings report is just what investors wanted to see.
- Zacks•6 months ago
What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?
Pacific Biosciences (PACB) is likely to witness year-over-year decline in product revenues.
- Zacks•6 months ago
Pacific Biosciences Hurt by Competition in Niche Markets
Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.
- Motley Fool•7 months ago
Better Buy: Illumina, Inc. vs. Pacific Biosciences
One of these vendors of gene sequencing instruments is flexing its muscles and the other is struggling.
